Plasbumin-25 Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to established use in shock and hypovolemia, growth of critical care medicine, reliance on plasma albumin therapies, increasing surgical procedures, hospital protocol adoption.

The growth in the forecast period can be attributed to rising liver disease incidence, increasing icu admissions, growth in burn and trauma cases, expansion of hospital infrastructure, steady demand for plasma proteins. Major trends in the forecast period include high use of concentrated albumin solutions, rising demand in critical care management, preference for volume expansion therapies, growth in surgical and icu applications, continued reliance on plasma derived proteins.

The rising prevalence of liver disorders is expected to drive the growth of the Plasbumin-25 market in the coming years. Liver disorders encompass a range of conditions that impair liver function, including cirrhosis, hepatitis, fatty liver disease, and liver cancer. The incidence of these disorders is increasing due to factors such as higher rates of alcohol consumption, obesity, diabetes, and viral infections like hepatitis. Plasbumin-25 is used in liver disease management to restore albumin levels in conditions such as cirrhosis, hepatic failure, and ascites, helping regulate fluid balance and prevent complications. For example, in April 2024, the Office for Health Improvement and Disparities, a UK government body focused on health inequalities, reported that hospital admissions for liver disease in England rose to 85,665, corresponding to a directly standardized rate of 155.2 per 100,000 population, marking an increase compared to previous years. Admissions due to alcoholic liver disease alone totaled 27,085, highlighting a continued rise in alcohol-related liver complications. Therefore, the rising prevalence of liver disorders is driving the Plasbumin-25 market.

The growth of healthcare spending is also expected to support the expansion of the Plasbumin-25 market. Healthcare spending refers to the total expenditure on medical goods, services, insurance, and health-related activities within an economy. This spending is increasing due to factors such as expanded insurance coverage and broader access to medical services, which lead to greater utilization of healthcare facilities, treatments, and medications. Higher healthcare expenditure directly increases the demand for albumin-based therapies like Plasbumin-25, which are critical for treating serious medical conditions in hospital and clinical settings. For instance, in November 2023, the Canadian Institute for Health Information, a Canada-based institute, reported that total health spending in Canada was projected to reach $344 billion in 2023, or $8,740 per person, representing a 2.8% increase compared to 2022, which saw only 1.5% growth. Therefore, growing healthcare spending is driving the Plasbumin-25 market.

The increasing number of road fatalities is further expected to propel the Plasbumin-25 market. Road fatalities refer to deaths resulting from injuries sustained in traffic accidents or road-related incidents. The rise in fatalities is attributed to higher vehicle speeds, distracted driving such as mobile phone use, insufficient road safety measures, urbanization, and the increasing number of vehicles, which lead to more frequent and severe accidents. Plasbumin-25 is commonly used to treat hypovolemic shock caused by accidents, severe burns, or trauma involving significant blood or fluid loss. For example, in February 2023, Statistisches Bundesamt, a Germany-based federal statistical authority, reported approximately 21,600 individuals were injured in road traffic incidents, a 5% increase from 2022, and the number of fatalities rose by 13, totaling 167 in February 2023. Therefore, the increasing number of road fatalities is driving the Plasbumin-25 market.

Major companies operating in the plasbumin-25 market are Grifols S.A.

North America was the largest region in the plasbumin-25 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasbumin-25 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the plasbumin-25 market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have affected the plasbumin-25 market by increasing costs associated with plasma sourcing, fractionation equipment, and cold chain logistics required for albumin distribution. These impacts are most evident in hospitals across Asia Pacific and Europe that rely on imported plasma derived products. Higher import duties have placed pressure on procurement budgets for critical care therapies. Distribution timelines have also been influenced by customs clearance requirements. At the same time, tariffs are encouraging regional plasma processing investments and strengthening domestic albumin supply chains.

The plasbumin-25 market research report is one of a series of new reports that provides plasbumin-25 market statistics, including plasbumin-25 industry global market size, regional shares, competitors with a plasbumin-25 market share, detailed plasbumin-25 market segments, market trends and opportunities, and any further data you may need to thrive in the plasbumin-25 industry. This plasbumin-25 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Plasbumin-25 is a human albumin solution used primarily to restore blood volume and maintain plasma colloid osmotic pressure in patients with conditions such as hypovolemia, burns, or liver cirrhosis. It aids in managing fluid balance during surgeries or in severe conditions like acute liver failure or shock. The 25% concentration allows effective treatment of hypoalbuminemia and supports critical functions in patients experiencing protein loss or fluid imbalances.

The main packaging sizes of Plasbumin-25 are 50 mL, 250 mL, and 500 mL. The 50 mL size is commonly used in hospitals or clinical settings for patients with moderate needs or in emergency care, providing a small and convenient dosage for short-term treatment. Indications include hypovolemic shock, hypoproteinemia, acute respiratory distress syndrome (ARDS), cardiopulmonary bypass, and acute liver failure. It is distributed through hospitals and clinics, retail pharmacies, and specialty pharmacies, and is used by adult and geriatric patients.

The plasbumin-25 market consists of sales of products including albumin solutions, immunoglobulins, clotting factors, and plasma-derived therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.